1368 related articles for article (PubMed ID: 23908005)
21. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody.
Nakashima R; Imura Y; Kobayashi S; Yukawa N; Yoshifuji H; Nojima T; Kawabata D; Ohmura K; Usui T; Fujii T; Okawa K; Mimori T
Rheumatology (Oxford); 2010 Mar; 49(3):433-40. PubMed ID: 20015976
[TBL] [Abstract][Full Text] [Related]
22. Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis.
Labrador-Horrillo M; Martinez MA; Selva-O'Callaghan A; Trallero-Araguas E; Balada E; Vilardell-Tarres M; Juárez C
J Immunol Res; 2014; 2014():290797. PubMed ID: 24741583
[TBL] [Abstract][Full Text] [Related]
23. Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease.
Motegi SI; Sekiguchi A; Toki S; Kishi C; Endo Y; Yasuda M; Ikeuchi H; Sakairi T; Hara K; Yamaguchi K; Maeno T; Hiromura K; Ishikawa O
Eur J Dermatol; 2019 Oct; 29(5):511-517. PubMed ID: 31617496
[TBL] [Abstract][Full Text] [Related]
24. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease.
Sato S; Hoshino K; Satoh T; Fujita T; Kawakami Y; Fujita T; Kuwana M
Arthritis Rheum; 2009 Jul; 60(7):2193-200. PubMed ID: 19565506
[TBL] [Abstract][Full Text] [Related]
25. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis.
Gono T; Kawaguchi Y; Satoh T; Kuwana M; Katsumata Y; Takagi K; Masuda I; Tochimoto A; Baba S; Okamoto Y; Ota Y; Yamanaka H
Rheumatology (Oxford); 2010 Sep; 49(9):1713-9. PubMed ID: 20498012
[TBL] [Abstract][Full Text] [Related]
26. Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease.
Yoshida N; Okamoto M; Kaieda S; Fujimoto K; Ebata T; Tajiri M; Nakamura M; Tominaga M; Wakasugi D; Kawayama T; Kuwana M; Mimori T; Ida H; Hoshino T
Respir Investig; 2017 Jan; 55(1):24-32. PubMed ID: 28012490
[TBL] [Abstract][Full Text] [Related]
27. Neutrophil extracellular traps may contribute to interstitial lung disease associated with anti-MDA5 autoantibody positive dermatomyositis.
Peng Y; Zhang S; Zhao Y; Liu Y; Yan B
Clin Rheumatol; 2018 Jan; 37(1):107-115. PubMed ID: 28842784
[TBL] [Abstract][Full Text] [Related]
28. Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis.
Xu Y; Yang CS; Li YJ; Liu XD; Wang JN; Zhao Q; Xiao WG; Yang PT
Clin Rheumatol; 2016 Jan; 35(1):113-6. PubMed ID: 26660480
[TBL] [Abstract][Full Text] [Related]
29. Clinical Heterogeneity of Interstitial Lung Disease in Polymyositis and Dermatomyositis Patients With or Without Specific Autoantibodies.
Chen F; Li S; Wang T; Shi J; Wang G
Am J Med Sci; 2018 Jan; 355(1):48-53. PubMed ID: 29289262
[TBL] [Abstract][Full Text] [Related]
30. Myositis-specific autoantibodies in dermatomyositis/polymyositis with interstitial lung disease.
Li L; Wang H; Wang Q; Wu C; Liu C; Zhang Y; Cheng L; Zeng X; Zhang F; Li Y
J Neurol Sci; 2019 Feb; 397():123-128. PubMed ID: 30616054
[TBL] [Abstract][Full Text] [Related]
31. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease.
Ye Y; Fu Q; Wang R; Guo Q; Bao C
J Clin Lab Anal; 2019 Oct; 33(8):e22978. PubMed ID: 31301087
[TBL] [Abstract][Full Text] [Related]
32. Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review.
Huang K; Vinik O; Shojania K; Yeung J; Shupak R; Nimmo M; Avina-Zubieta JA
Rheumatol Int; 2019 Nov; 39(11):1971-1981. PubMed ID: 31375890
[TBL] [Abstract][Full Text] [Related]
33. Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease.
Xu A; Ye Y; Fu Q; Lian X; Chen S; Guo Q; Lu LJ; Dai M; Lv X; Bao C
Rheumatology (Oxford); 2021 Jul; 60(7):3343-3351. PubMed ID: 33331866
[TBL] [Abstract][Full Text] [Related]
34. Predictors of Poor Outcome of Anti-MDA5-Associated Rapidly Progressive Interstitial Lung Disease in a Chinese Cohort with Dermatomyositis.
Li Y; Li Y; Wu J; Miao M; Gao X; Cai W; Shao M; Zhang X; Xu Y; Cong L; He J; Sun X
J Immunol Res; 2020; 2020():2024869. PubMed ID: 33299896
[TBL] [Abstract][Full Text] [Related]
35. Successful polymyxin B hemoperfusion treatment associated with serial reduction of serum anti-CADM-140/MDA5 antibody levels in rapidly progressive interstitial lung disease with amyopathic dermatomyositis.
Teruya A; Kawamura K; Ichikado K; Sato S; Yasuda Y; Yoshioka M
Chest; 2013 Dec; 144(6):1934-1936. PubMed ID: 24297126
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Role of Interferon-λ3 in Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis-Associated Interstitial Lung Disease.
Fukada A; Fujisawa T; Hozumi H; Koda K; Akamatsu T; Oyama Y; Satake Y; Niwa M; Kaida Y; Matsuda H; Yokomura K; Koshimizu N; Toyoshima M; Imokawa S; Hashimoto D; Yoshida A; Gono T; Kuwana M; Yamano Y; Kondoh Y; Yamashita K; Maekawa M; Mori K; Inoue Y; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Inui N; Suda T
Arthritis Rheumatol; 2024 May; 76(5):796-805. PubMed ID: 38146102
[TBL] [Abstract][Full Text] [Related]
37. Antimelanoma Differentiation-associated Gene 5 Antibody: Expanding the Clinical Spectrum in North American Patients with Dermatomyositis.
Moghadam-Kia S; Oddis CV; Sato S; Kuwana M; Aggarwal R
J Rheumatol; 2017 Mar; 44(3):319-325. PubMed ID: 28089977
[TBL] [Abstract][Full Text] [Related]
38. Detection of anti-CADM-140/MDA5 antibodies in a patient with classic dermatomyositis developing rapidly progressive interstitial lung disease.
Miyake M; Sakai A; Nishijima C; Kita T; Nitta E; Kawashima A; Hamaguchi Y; Fujimoto M; Inaoki M
J Dermatol; 2014 Jul; 41(7):664-5. PubMed ID: 24930560
[No Abstract] [Full Text] [Related]
39. Rapidly progressive interstitial lung disease due to anti-MDA5 antibodies without skin involvement: a case report and literature review.
González-Moreno J; Raya-Cruz M; Losada-Lopez I; Cacheda AP; Oliver C; Colom B
Rheumatol Int; 2018 Jul; 38(7):1293-1296. PubMed ID: 29417209
[TBL] [Abstract][Full Text] [Related]
40. Anti-MDA5 antibody as a potential diagnostic and prognostic biomarker in patients with dermatomyositis.
Li L; Wang Q; Yang F; Wu C; Chen S; Wen X; Liu C; Li Y
Oncotarget; 2017 Apr; 8(16):26552-26564. PubMed ID: 28460448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
